106429-29-2

Basic information

• Product Name: 1H-Benzimidazol-5-ylmethanol
• Synonyms: 5-(HYDROXYMETHYL)-1H-BENZIMIDAZOLE 97;1H-BENZIMIDAZOL-5-YLMETHANOL;5-(Hydroxymethyl)-1H-benzimidazole;5-(Hydroxymethyl)-1H-benzimidazole 97%;1H-Benzimidazole-5-methanol(9CI);(1H-benzo[d]imidazol-5-yl)methanol
• CAS NO: 106429-29-2
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.16
• Product Categories: BENZIMIDAZOLE
• Mol File: 106429-29-2.mol

Chemical Properties

• Melting Point: 128.5-131
• Boiling Point: 469.534 °C at 760 mmHg
• Flash Point: 237.766 °C
• Appearance: /
• Density: 1.36 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.721
• PKA: 12.48±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazol-5-ylmethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazol-5-ylmethanol(106429-29-2)
• EPA Substance Registry System: 1H-Benzimidazol-5-ylmethanol(106429-29-2)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38-41-37/38
• Safety Statements: 22-26-36/37/39-39
• Hazardous Substances Data: 106429-29-2(Hazardous Substances Data)

Usage

Uses

Given the provided materials, there are no specific applications listed for 1H-Benzimidazol-5-ylmethanol. However, its use is primarily in the synthesis of novel chemical structures due to its benzimidazole core, which is a common feature in biologically active compounds. If there were specific applications in different industries, they would be listed as follows:
Used in [Application Industry]:
1H-Benzimidazol-5-ylmethanol is used as [application type] for [application reason]
Since the provided materials do not specify any particular industry or application, this section remains general. Its role in the synthesis of other compounds suggests potential uses in pharmaceuticals, agrochemicals, or other industries where novel chemical entities are being developed.

InChI:InChI=1/C8H8N2O/c11-4-6-1-2-7-8(3-6)10-5-9-7/h1-3,5,11H,4H2,(H,9,10)

Upstream product

• 15788-16-6 5-benzimidazolecarboxylic acid 
• 58842-61-8 benzimidazole-5-carboxylic acid ethyl ester 
• 304-59-6 Rochelle's salt 
• 141-78-6 ethyl acetate 
• 58842-61-8 ethyl benzimidazole-6-carboxylate 
• 619-05-6 3,4-diaminobenzoic acid 
• 473895-86-2 (1⁽³⁾H-benzimidazol-5-yl)-acetic acid 
• 774486-29-2 5-chloromethyl-1⁽³⁾H-benzoimidazole 
• 15788-16-6 1H-benzimidazole-6-carboxylic acid 

Downstream Products

• 26663-77-4 methyl 1H-benzo[d]imidazole-5-carboxylate 
• 181867-19-6 1-methyl-1H-benzo[d]imidazole-6-carbaldehyde 
• 279226-70-9 1-methyl-1H-benzo[d]imidazole-5-carbaldehyde 
• 267875-43-4 6-azidomethyl-1H-benzo [d]imidazole 
• 164648-60-6 1H-1,3-benzodiazol-6-ylmethanamine 
• 1392002-34-4 N-(1H-1,3-benzodiazol-6-ylmethyl)-4-(4-fluorophenoxy)piperidine-1-carboxamide 

Relevant articles and documents

Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells

Resistance to combretastatin A-4 is mediated by metabolic modification of the phenolic hydroxyl and ether groups of the 3-hydroxy-4-methoxyphenyl (B ring). Replacement of the B ring of combretastatin A-4 by a N-methyl-5-indolyl reduces tubulin polymerization inhibition (TPI) and cytotoxicity against human cancer cell lines but cyano, methoxycarbonyl, formyl, and hydroxyiminomethyl substitutions at the indole 3-position restores potent TPI and cytotoxicity against sensitive human cancer cell lines. These highly potent substituted derivatives displayed low nanomolar cytotoxicity against several human cancer cell lines due to tubulin inhibition, as shown by cell cycle analysis, confocal microscopy, and tubulin polymerization inhibitory activity studies, and promoted cell killing mediated by caspase-3 activation. Binding at the colchicine site was suggested by molecular modeling studies. Substituted combretastatins displayed higher potencies than the isomeric isocombretastatins and the highest potencies were achieved for the hydroxyiminomethyl (21) and cyano (23) groups, with TPI values in the submicromolar range and cytotoxicities in the nanomolar and subnanomolar range. Dose-response and time-course studies showed that drug concentrations as low as 1 nM (23) or 10 nM (21) led to a complete G2/M cell cycle arrest after 15 h treatment followed by a high apoptosis-like cell response after 48–72 h treatment. The P-glycoprotein antagonist verapamil increased 21 and 23 cytotoxicity to IC50 values of 10?10 M, and highly potentiated the cytotoxic activity in 100-fold of the CHO derivative (17), in A-549 human non-small cell lung cancer cells. The cyano substituted indolecombretastatin 23 is by itself highly potent against rather resistant HT-29 and A-549 cell lines. A 3,4,5-trimethoxyphenyl ring always afforded more potent derivatives than a 2,3,4-trimethoxyphenyl ring.

ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND

The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4CRBN E3 ubiquitin ligase.

Multi-target inhibitor acting on QC and GSK-3[beta]

The invention discloses a multi-target inhibitor acting on QC and GSK-3[beta], wherein the multi-target inhibitor has the structural general formula shown in the specification; according to active center crystal structures of target QC and GSK-3[beta] zymoprotein, with synthesis of multiple high-activity pharmacophores, the multi-target inhibitor capable of acting on QC and GSK-3[beta] at the sametime is prepared through skeletal transition and recombination design; the multi-target inhibitor is a high-activity molecule with multiple target points, the molecular structure diversity of a leaddrug is remarkably expanded, and research and development of innovative anti-AD drugs and AD diagnostic kits are actively promoted.

Preparation method and application of multi-target inhibitor acting on QC and GSK-3beta

The invention discloses a preparation method and application of a multi-target inhibitor acting on QC and GSK-3 beta. The structural general formula of the multi-target inhibitor prepared by the method is shown in the specification. According to the invention, according to active center crystal structures of target QC and GSK-3 beta zymoprotein, multiple high-activity pharmacophores are integrated, the multi-target inhibitor capable of acting on QC and GSK-3 beta at the same time is prepared through framework transition and recombination design, the multi-target inhibitor is molecules with multiple target points and high activity, the molecular structure diversity of a lead drug is remarkably expanded, and the research and development of innovative anti-AD drugs and AD diagnostic kits areactively promoted, and the preparation method of the multi-target inhibitor provided by the invention is simple and easy to operate.

Substituted Pyran Derivatives

Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter system

PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS

A compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof (I) Wherein Y, Z, R3, U, R4, m and n are as defined in the claims.

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

NOVEL JNK INHIBITORS

Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.

OXIME COMPOUNDS AND THE USE THEREOF

The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CRsu

A facile synthesis of 5(6)-(chloromethyl)benzimidazoles: Replacement of a sulfonic acid functionality by chlorine

(Chemical Equation Presented) Valuable new synthetic intermediates, 5(6)-(chloromethyl)benzimidazoles, were prepared by the facile elimination of sulfur dioxide under the influence of thionyl chloride from benzimidazole-5(6)- methanesulfonic acids easily